A Practical Approach to the Diagnosis and Therapy of Helicobacter pylori Infection

Antimicrobics and Infectious Diseases Newsletter

Volumn 16, Issue 11, 1997, Pages 81-86

  Stratton, Charles W ^a   Coudron, Philip E ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0041543099     PISSN: 1069417X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1069-417x(00)80036-9     Document Type: Article

References (111)

1. Abu-Mahfouz MZ, Prasad VM, Santogade P, Cutler AF: 1997. HP recurrence after successful eradication: 5-year follow-up in the United States. Am J Gastroenterol 92:2025-2027.
2. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W: 1998. Primary and acquired Helicobacter pylori resistance of clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 93:386-389.
3. Adamek RJ, Suerbaum JS, Pfaffenbach B, Wegner M: 1996. Influence of H. pylori resistance to antibiotics on eradication outcome. Gut 39(Suppl 2):A5.
4. Andersen LP, Kiilerick S, Pedersen G, et al.: 1998. An analysis of seven different methods to diagnose Helicobacter pylori infections. Scand J Gastroenterol 33:24-30.
5. Axon ATR: 1994. The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori - an update. Scand J Gastroenterol 205:31-37.
6. Berry V, Jennings K, Woodnutt G: 1995. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori. Antimicrob Agents Chemother 39:1859-1861.
7. Blaser MJ: 1998. Helicobacter pylori and gastric diseases. Br Med J 316:1507-1510.
8. Blaser MJ: 1992. Helicobacter pylori: its role in disease. Clin Infect Dis 15:386-391.
9. Blaser MJ: 1997. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet 349:1020-1022.
10. Blaser MJ, Parsonnet J: 1994. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest 94:4-8.
11. Bode G, Mauch F, Malfertheiner P: 1993. The coccoid form of Helicobacter pylori. Criteria for their viability. Epidemiol Infect 111:483-490.
12. Borody TJ, Andrews P, Fracchia G, Brandi S, Shortis NP, Bae H: 1995. Omeprazole enhances efficacy of triple therapy in eradication Helicobacter pylori. Gut 37:477-481.
13. Breslin NP, O'Morain CA: 1997. Noninvasive diagnosis of Helicobacter pylori infection: a review. Helicobacter 2:111-117.
14. Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY: 1998. How do clinicians in the U.S. manage Helicobacter pylori- related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol 93:553-561.
15. Brown KE, Peura DA: 1993. Diagnosis of Helicobacter pylori infection. Gastroenterol Clin North Am 22:105-115.
16. Buckley MJM, Xia HX, Hyde DM, Keane CT, O'Morain CA: 1997. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Digest Dis Sci 42:2111-2115.
17. Cardaci G, Lambert JR, King RG, Onishi N, Midolo P: 1995. Reduced amoxicillin uptake into human gastric mucosa when gastric juice pH is high. Antimicrob Agents Chemother 39:2084-2087.
18. Cayla R, Zerbib R, Talbi P, Megraud F, Lamouliatte H: 1995. Pre- and post-treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment of failure. Gut 37(Suppl 1): A55.
19. Cederbrant G, Kanlmeter Ljungh A: 1992. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 29:115-120.
20. Chan WY, Hui PK, Leung KM, Chow J, Kwok F, Ng CS: 1994. Coccoid forms of Helicobacter pylori in the human stomach. Am J Clin Pathol 102:503-507.
21. Chiba N, Rao BV, Rademaker JW, Hunt RH: 1992. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 87:1716-1727.
22. Cooreman MP, Krausgrill P, Hengels KJ: 1993. Local gastric and serum amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother 37:1506-1509.
23. Correa P: 1997. Helicobacter pylori as a pathogen and carcinogen. J Physiol Pharmacol 48(Suppl 4):19-24.
24. Coudron, PE, Kirby DF: 1989. Comparison of rapid urease tests, staining techniques, and growth on different solid media for detection of Campylobacter pylori. J Clin Microbiol 27:1527-1530.
25. Coudron P, Stratton C: 1995. Factors affecting growth and susceptibility testing of Helicobacter pylori in liquid media. J Clin Microbiol 33:1028-30.
26. Coudron, PE, Stratton CW: 1995. Use of time-kill methodology to assess antimicrobial combinations against metronidazole-susceptible and metronidazole-resistant strains of Helicobacter pylori. Antimicrob Agents Chemother 39:2641-2644.
27. Coudron PE, Stratton CW: 1995. Utilization of time-kill kinetic methodologies for assessing the bactericidal activities of ampicillin and bismuth, alone and in combination, against Helicobacter pylori in stationary and logarithmic growth phases. Antimicrob Agents Chemother 39:66-69.
28. Cutler AF, Havstad S, Ma CK, et al.: 1995. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterol 109:136-141.
29. Damianos AJ, McCarrity TJ: 1997. Treatment strategies for Helicobacter pylori infection. Am Fam Physician 55:2765-2774.
30. Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Klokman JJ, Vandenbrocuke-Brauls JE: 1996. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 142:37-42.
31. De Boer WA, Tytgat GNJ: 1995. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 30:401-407.
32. De Boer W, Driessen W, Jansz A, Tytgat G: 1995. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 345:817-820.
33. DeCross AJ, Marshall BJ: 1993. The role of Helicobacter pylori in acid-peptic disease. Am J Med Sci 306:381-392.
34. DeCross A, Marshall B, McCallum R, Hoffman S, Barrett L, Guerrant R: 1993. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 31:1971-1974.
35. Dore MP, Osato MS, Dwon DH, Graham DY, el-Zaatari FA: 1998. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis 27:84-89.
36. Dunn BE, Cohen H, Blaser MJ: 1997. Helicobacter pylori. Clin Microbiol Rev 10:720-741.
37. Duggan AE, Tolley K, Hawkey CJ, Logan RF: 1998. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. Brit Med J 316:1648-1654.
38. Ebell MH: 1998. Breath test and serologic testing for Helicobacter pylori. J Am Board Fam Pract 11:170-171.
39. Ebell MH, Warbasse L, Brenner C: 1997. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 44:545-455.
40. Engstrand L, Graham DY, Scheynius A, Genta R, el-Zaatari F: 1997. Is the sanctuary where Helicobactor pylori avoids antibacterial treatment intracellular? Am J Clin Pathol 108:504-509.
41. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC: 1997. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 39:5-12.
42. Evans DG, Evans DJ Jr, Graham DY: 1992. Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterol 102:1557-1567.
43. Feldman M: 1994. The acid test. Making clinical sense of the Consensus Conference on Helicobacter pylori. JAMA 272:70-71.
44. Fendrick AM, Fennerty MB, Margaret N, et al.: 1997. Symptom status and the desire for H. pylori confirmatory testing after eradication treatment. Gastroenterol 112:A14.
45. Fennerty MB. Helicobacter pylori. Arch Intern Med 1994 154:721-727.
46. Forbes GM, Glaser ME, Cullen DJE, et al.: 1994. Duodenal ulcer treated with Helicobacter pylori eradication: seven year follow-up. Lancet 343:258-260.
47. Forman D: 1998. Helicobacter pylori infection and cancer. Br Med Bull 54:71-78.
48. Gisbert JP, Boixeda D, De Rafael L, Moreno L, Martin de Argila C, Bermejo F, Redondo C: 1996. Which factors influence on the success of "classic" triple therapy in Helicobacter pylori eradication? Gut 39(Suppl 2):A7.
49. Glupczynski Y: 1998. Microbiological and serological diagnostic tests for Helicobacter pylori: an overview. Br Med Bull 54:175-186.
50. Goddard AF, Logan RPH: 1996. Antimicrobial resistance and Helicobacter pylori. J Antimicrob Chemother 37:639-643.
51. Goldman RC, Zakula D, Flamm R, Beyer J, Capobianco J: 1994. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 38:1496-1500.
52. Goodwin A, Kersulyte D, Sisson G, Veldhuyzen van Santen SJ, Berg DE, Hoffman PS: 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol Microbiol 28:383-393.
53. Gotoh A, Kawakami Y, Akamatsu T, Katsuyama T: 1997. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. Microbiol Immunol 41:865-869.
54. Graham DY, de Boer A, Tytgat GNJ: 1996. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 91:1072-1076.
55. Graham DY: 1994. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem. Am J Gastroenterol 89:469-472.
56. Graham DY, Lew GM, Malaty HM, Evans D, Klein P, Alpert L: 1992. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterol 102:493-496.
57. Graham DY, Lew GM, Klein PD, et al.: 1992. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116:705-8.
58. Graham DY: 1993. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 328:349-350.
59. Grove DI, Koutsouridis G, Cummins AG: 1998. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. Pathol 30:183-187.
60. Gustavson LE, Kaiser JF, Edmonds AL, Locke CS, DeBartolo ML, Schneck ML: 1995. Effect of omeproazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 39:2078-2083.
61. Harris A: 1998. Current regimens for treatment of Helicobacter pylori infection. Br Med Bull 54:195-205.
62. Hartvig Hartzen SH, Percival Andersen LP, Bremmelgaard A, et al.: 1997. Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium inoculum and incubation time. Antimicrob Agents Chemother 41:2634-2639.
63. Huang JQ, Sridhar S, Chen Y, Hunt RH: 1998. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterol 114:1169-1179.
64. Hulten K, Rigo R, Gustafsson I, Engstrand L: 1996. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob Agents Chemother 40:2727-2731.
65. Hunt R, Thomson AB: 1998. Canadian Helicobacter pylori consensus conference. Can J Gastroenterol 12:31-41.
66. Iwahi, T, Satoh H, Nakao M, et al.: 1991. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 35:490-496.
67. Jorgensen MA, Manos J, Mendez GL, Hazell SL: 1998. The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction? J Antimicrob Chemother 41:67-75.
68. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY: 1998. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 93:574-578.
69. Karim QN, Logan RPH: 1996. Emerging patterns of Helicobacter pylori antimicrobial susceptibility in Europe. Gut 39:A51.
70. Labenz J, Borsch G: 1994. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut 35:19-22.
71. Lerang F, Moum B, Haug JB, et al.: 1997. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 92:248-253.
72. Lerang F, Moum B, Ragnhildstveit E, et al.: 1998. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with high frequency of metronidazole resistance. Am J Gastroenterol 93:212-216.
73. Levin TR, Schmittdiel JA, Henning JM, et al.: 1998. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 93:743-747.
74. Ling KT, Cheng AF, Sung JJ, Yiu PY, Chung SS: 1996. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter 1:57-61.
75. Marshall BJ: 1993. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin N Am 22:183-198.
76. Marshall BJ, Warren JR: 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1311-1315.
77. McColl KE, el-Nujumi A, Murray LS, et al.: 1998. Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcers. Gut 42:618-622.
78. Megraud F: 1998. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 54:207-216.
79. Megraud F, Occhialini A, Doermann HP: 1997. Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation. J Physiol Pharmacol 48(Suppl 4):25-38.
80. National Institutes of Health: 1994. Helicobacter pylori in peptic ulcer disease. NIH Consensus Statement 12:1-23.
81. Ogata M, Araki K, Ogata TL: 1998. An electron microscopic study of Helicobacter pylori in the surface mucous gel layer. Histol Histopathol 13:347-58.
82. Palli D: 1997. Gastric cancer and Helicobacter pylori: a critical evaluation of the epidemiological evidence. Helicobacter 2(Suppl 1):S56-60.
83. Parsonnet J, Harris RA, Hack HM, Owens DK: 1996. Modeling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinicial trials. Lancet 348:150-154.
84. Parsonnet J: 1998. Helicobacter pylori. Infect Dis North Am 12:185-197.
85. Peterson WL, Graham DY, Marshall B, et al.: 1993. Clarithromycin as monotherapy for eradication of Helicobacter pylori : a randomized, double-blind trial. Am J Gastroenterol 88:1860-1864.
86. Proceedings of the American Digestive Health Foundation; International Update Conference on Helicobacter pyori. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterol 1997, 113(Suppl 1):S4-8.
87. Rabeneck L, Graham DY: 1997. Helicobacter pylori: when to test, when to treat. Ann Intern Med 126:315-316.
88. Rautelin H, Seppala K, Renkonen OV, Vainio U, Kosunen TU: 1992. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 36:163-166.
89. Salcedo JA, Al-Kawas F: 1998. Treatment of Helicobacter pylori infection. Arch Intern Med 158:842-851.
90. Satoh K, Kimura K, Taniguchi Y, et al.: 1998. Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. Am J Gastroenterol 93:569-573.
91. Silverstein MD, Petterson T, Talley NJ: 1996. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterol 110:72-83.
92. Sjöström, JE, Fryklund J, Kuhler T, Larsson H: 1996. In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions. Antimicrob Agents Chemother 40:621-626.
93. Sjöström JE, Kühler T, Larsson H: 1997. Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob Agents Chemother 41:1797-1801.
94. Sjöström, JE, Larsson H: 1996. Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant. J Med Microbiol 44:425-433.
95. Sorberg M, Hanberger H, Nilsson M, Bjorkman A, Nilsson LE: 1998. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 42:1222-1228.
96. Sörberg M, Hanberger H, Nilsson M, Nilsson LE: 1996. Morphologic conversion of Helicobacter pylori from bacillary form to coccoid form evaluated by bioluminescence, microscopy, and viable count. Eur J Microbiol Infect Dis 15:216-219.
97. Sörberg M, Hanberger H, Nilsson M, Nillsson LE: 1997. Pharmacodynamic effects of antibiotics and acid pump inhibitors on Helicobacter pylori. Antimicrob Agents Chemother 41:2218-2233.
98. Stratton CW, Coudron PE: 1997. Bismuth-mediated disruption of the glycocalyx/ cell wall of Helicobacter pylori: evidence for a mechanism of action for bismuth salts. Gastroenterol 112:A1098.
99. Sung JJY, Chung SCS, Ling TKW, et al.: 1995. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 332:139-142.
100. Taylor JL, Zagari M, Murphy K, Freston JW: 1997. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 157:87-97.
101. The European Helicobacter pylori Study Group: 1997. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 41:8-13.
102. Tompkins DS, Perkin J, Smith C: 1997. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 2:185-187.
103. Tytgat GNJ: 1997. Antimicrobial therapy for Helicobacter pylori infection. Helicobacter 2(Suppl 1):S81-88.
104. Unge P: 1996. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 31(Suppl 215):74-81.
105. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ: 1996. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1:6-19.
106. van der Hulst RWM, Rauws EAJ, Köycü B, et al.: 1997. Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis 176:196-200.
107. van der Hulst RWM, van der Ende A, Homan A, Roorda P, Dankert J, Tytgat GNJ: 1998. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut 42:166-169.
108. Van Zwet AA, Thijs JC, De Graaf B: 1995. Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 39:250-252.
109. Versalovic J, Shortridge D, Dibler D, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF: 1996. Mutations in 23s rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 40:477-480.
110. Wermeille J, Zelger G, Cunningham M: 1998. The eradication treatments of Helicobacter pylori. Pharm World Sci 20:1-17.
111. Wotherspoon AC: 1998. Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori. Ann Rev Med 49:289-299.